HUMAN MONOCLONAL ANTIBODIES TO TNF-? — AGENT OF CHOICE IN TREATMENT OF SEVERE JUVENILE RHEUMATOID ARTHRITIS WITH UVEITIS

The article presents a case report of an early debut and severe clinical course of juvenile rheumatoid arthritis with eyes’ lesion. Authors describe successful administration of human monoclonal antibodies to tumor necrotizing factor (TNF) — adalimumab. In 2 weeks of treatment the morning joint stiffness was stopped, in 4 weeks exudative alterations in affected joints were vanished, and the range of their motions increased. Results of laboratory tests: ESR and concentration of C-reactive protein in plasma were normalized in 6 weeks. Adalimumab initiated development of remission of bilateral uveitis in 8 weeks.Key words: children, juvenile rheumatoid arthritis, rheumatoid uveitis, adalimumab, treatment.(Voprosy sovremennoi pediatrii — Current Pediatrics. – 2010;9(3):140-146)